HHSC to Implement Clinical Prior Authorization for Antimigraine Agents-Ergot Derivatives on June 6, 2023

May 17, 2023

On June 6, 2023, HHSC will implement the antimigraine agents-ergot derivatives clinical prior authorization (PDF). The Texas Drug Utilization Review Board approved these clinical prior authorizations on April 28, 2023.

These clinical prior authorizations are optional for managed care organizations (MCOs).

The Pharmacy Clinical Prior Authorization Assistance Chart shows each MCO's prior authorizations and how these authorizations relate to those that are used for processing fee-for-service Medicaid claims. This chart is updated quarterly. Providers can refer to the MCO Resources page for links to each MCO's list of clinical prior authorizations.